Top segments and regional performance

Last year, the company generated ‪944.00 M‬ USD, the most of which — ‪943.71 M‬ USD — came from its top-performing segment, RNA-targeted Medicines, compared to ‪705.14 M‬ USD the previous year. The greatest contribution came from United States, which accounted for ‪943.71 M‬ USD last year, with ‪705.14 M‬ USD the year before.